Analyst firms · Citigroup · PODD

Citigroup PODD price target and rating history

Insulet Corporation (PODD) · Health Care

Citigroup rates Insulet Corporation (PODD) Neutral with a $230 price target, as of its latest action on Apr 7, 2026. It has published 3 rating actions on PODD since July 2022, including 1 upgrade and 2 downgrades. Across 10 firms with a PODD price target in the last 12 months, the median target is $182. Citigroup's $230 is 26% above that.

Current rating

Neutral

Price target

$230

Median target, all firms

$182

Actions on PODD

3

Citigroup price target on PODD

Every Citigroup rating on PODD

• Apr 7, 2026
  DowngradeCitigroup downgrades to Neutral from Buy, price target $230
• Aug 21, 2023
  UpgradeCitigroup upgrades to Buy from Neutral, price target $273 to $265
• Jul 11, 2022
  DowngradeCitigroup downgrades to Neutral from Buy, price target $310 to $250

How other firms rate PODD

Each firm's latest rating and stated target in the last 12 months.

Questions about Citigroup and PODD

What is Citigroup's price target for PODD?

Citigroup's latest stated price target for Insulet Corporation (PODD) is $230, from its action on Apr 7, 2026.

What is Citigroup's rating on PODD?

Citigroup rates PODD Neutral, a neutral rating, as of Apr 7, 2026.

When did Citigroup last change its view on PODD?

On Apr 7, 2026, Citigroup downgrades to Neutral from Buy, price target $230.

How does Citigroup's PODD target compare with other analysts?

Across 10 firms with a PODD price target in the last 12 months, the median target is $182. Citigroup's $230 is 26% above that.

More PODD rating histories

• Barclays3
• Leerink Partners4
• Oppenheimer3
• UBS3
• Wolfe Research4
• Morgan Stanley5

All Citigroup ratingsPODD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.